



About the Janssen Pharmaceutical Companies

At Janssen, the Pharmaceutical Companies of Johnson & Johnson, we tackle society's most pressing health challenges, connecting big ideas to the resources we need to make them a reality. By seeking out medical breakthroughs wherever they occur, leveraging internal expertise and embracing external science, we aim to bring the best solutions to the people who need them.

We focus on areas of medicine where we can make the biggest difference in [Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology and Pulmonary Hypertension](#). We work together – across business, academia, governments and society – to lead healthcare's ongoing reinvention. At Janssen, we collaborate with the world for the health of everyone in it.

[Discovery, Product Development and Supply \(DPDS\)](#) is a world class, end-to-end discovery and development organization that partners with therapeutic areas and drives strategies to create transformational medicines for patients. DPDS' six global functions provide small molecule and large molecule discovery, de-risking, product development, formulation, and clinical supply chain expertise. DPDS' medicinal and process chemists work together to enable the discovery and advancement of small molecules through the development phase.

Are you serious about research? So are we. We're driven by our belief that "patients are waiting" and there is no time to waste. We're growing our internal invention teams to discover new therapeutics. And we're looking for bold scientists to join us. Go to www.careers.jnj.com Search word: discovery. Visit our website: www.janssen.com

Check out some recent publications to learn more about our science:

- *Scalability of Visible-Light-Induced Nickel Negishi Reactions: A Combination of Flow Photochemistry, Use of Solid Reagents, and In-Line NMR Monitoring.* *J. Org. Chem.* **2019**, *84*, 4748.
- *Photoredox-Mediated Heteroarylation of N-Protected Secondary Amines: Remarkable Selectivity of Azetidines.* *Org. Lett.* **2018**, *20*, 6003.
- *A Dipolar Cycloaddition Reaction to Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate.* *J. Med. Chem.* **2018**, *61*, 207.
- *A Copper-Catalyzed Tandem C-H ortho-Hydroxylation and N-N Bond-formation Transformation: Expedited Synthesis of 1-(ortho-Hydroxyaryl)-1H-indazoles.* *Eur. J. Org. Chem.* **2017**, 6604.

1.FORTUNE - The World's Most Admired Companies <http://fortune.com/worlds-most-admired-companies/johnson-johnson/>
2.Includes all clinically-relevant articles (original articles, reviews, and editorials, but not supplements and correspondence) published to-date in NEJM, JAMA, Lancet, Science, and Nature since 2014
3.PricewaterHouseCoopers. "2018 Global Innovation 1000 Study." <https://www.strategyand.pwc.com/innovation1000>

Employ approximately **10,000 scientists and researchers globally**

Ranked #1 in Pharmaceuticals on Fortune's Most Admired Companies List¹

JNJ Credo - set of principles that **puts the needs of patients first**

Personalized performance and development plan to support your career growth

Clinical/scientific community recognition in last 5 years²

38 NEJM/Lancet/JAMA & 28 Science/Nature articles published

Invested more than \$8.4 billion in pharmaceutical R&D in 2018, **ranked among the highest** in the industry³

JNJ Diversity and Inclusion vision: **be yourself and change the world**